181 related articles for article (PubMed ID: 7981452)
1. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1994; 31(1):117-27. PubMed ID: 7981452
[TBL] [Abstract][Full Text] [Related]
2. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1994; 31(1):129-38. PubMed ID: 7981453
[TBL] [Abstract][Full Text] [Related]
3. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
4. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
6. Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice.
Koibuchi Y; Iino Y; Uchida T; Andoh T; Horii Y; Nagasawa M; Horiguchi J; Maemura M; Takei H; Yokoe T; Morishita Y
Oncol Rep; 2000; 7(1):135-40. PubMed ID: 10601607
[TBL] [Abstract][Full Text] [Related]
7. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis MM; Robinson SP; Satyaswaroop PG; Jordan VC
Cancer Res; 1988 Feb; 48(4):812-5. PubMed ID: 3338079
[TBL] [Abstract][Full Text] [Related]
8. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.
Gottardis MM; Jiang SY; Jeng MH; Jordan VC
Cancer Res; 1989 Aug; 49(15):4090-3. PubMed ID: 2743303
[TBL] [Abstract][Full Text] [Related]
11. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.
Gottardis MM; Jordan VC
Cancer Res; 1988 Sep; 48(18):5183-7. PubMed ID: 3409244
[TBL] [Abstract][Full Text] [Related]
12. Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.
Gibson DF; Johnson DA; Goldstein D; Langan-Fahey SM; Borden EC; Jordan VC
Breast Cancer Res Treat; 1993; 25(2):141-50. PubMed ID: 8347846
[TBL] [Abstract][Full Text] [Related]
13. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.
Jordan VC; Gottardis MM; Robinson SP; Friedl A
J Steroid Biochem; 1989; 34(1-6):169-76. PubMed ID: 2626014
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
15. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice.
Ju YH; Doerge DR; Allred KF; Allred CD; Helferich WG
Cancer Res; 2002 May; 62(9):2474-7. PubMed ID: 11980635
[TBL] [Abstract][Full Text] [Related]
16. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Detre S; Riddler S; Salter J; A'Hern R; Dowsett M; Johnston SR
Cancer Res; 2003 Oct; 63(19):6516-22. PubMed ID: 14559845
[TBL] [Abstract][Full Text] [Related]
18. [Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method].
Kurebayashi J; Horiuchi R; Nakamura T; Iino Y; Ishida T; Takigawa H; Izuo M
Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1351-63. PubMed ID: 2965035
[TBL] [Abstract][Full Text] [Related]
19. Enhanced growth of an estrogen receptor-negative endometrial adenocarcinoma by estradiol in athymic mice.
Friedl A; Gottardis MM; Pink J; Buchler DA; Jordan VC
Cancer Res; 1989 Sep; 49(17):4758-64. PubMed ID: 2758409
[TBL] [Abstract][Full Text] [Related]
20. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
Schafer JM; Lee ES; Dardes RC; Bentrem D; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2001 Aug; 7(8):2505-12. PubMed ID: 11489833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
